Consensus Bio-Techne Corporation

Equities

TECH

US09073M1045

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
64.06 ^USD	+2.23%		+3.12%	-16.98%

Apr. 26	Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay	CI
Apr. 23	Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe	MT

Evolution of the average Target Price on Bio-Techne Corporation

Price target over the last 5 years

History of analyst recommendation changes

82893345c78b7c116d770aa2.d8nW5eoOaG8e77fnWSo5GsijgZ5fbZEYR1NOYIIyr1Q.AfquiK57LR9kofqgC35YaK_F7NklAOF1FQt6Ka9cwhE5jpyC3ntRDSrW4g~2183b111b7358defa95cb69bbf5a06d3

Analyst Recommendations on Bio-Techne Corporation

Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	Apr. 18	MT
RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating	Apr. 08	MT
Stephens Adjusts Bio-Techne's Price Target to $87 From $70, Keeps Overweight Rating	Feb. 02	MT
Deutsche Bank Cuts Bio-Techne Price Target to $85 From $88, Maintains Buy Rating	Feb. 02	MT
RBC Cuts Price Target on Bio-Techne to $75 From $85, Notes Revenue Growth Turned Negative, Keeps Sector Perform Rating	Feb. 02	MT
Stifel Nicolaus Downgrades Bio-Techne to Hold from Buy, $65 Price Target	Feb. 02	MT
UBS Initiates Coverage on Bio-Techne With Buy Rating, $80 Price Target	Dec. 07	MT
Deutsche Bank Cuts Bio-Techne Price Target to $70 From $100, Maintains Buy Rating	Nov. 01	MT
KeyBanc Cuts Price Target on Bio-Techne to $80 From $115, Maintains Overweight Rating	Nov. 01	MT
RBC Trims Price Target on Bio-Techne to $83 From $85, Keeps Sector Perform Rating	Nov. 01	MT
William Blair Initiates Coverage on Bio-Techne with Outperform Rating	23-08-28	MT
RBC Trims Bio-Techne's Price Target to $87 From $88, Keeps Sector Perform Rating	23-07-17	MT
RBC Trims Price Target on Bio-Techne to $88 From $90, Maintains Sector Perform Rating	23-05-15	MT
Baird Adjusts Price Target on Bio-Techne to $100 From $99, Maintains Outperform Rating	23-05-04	MT
RBC Lifts Price Target on Bio-Techne to $90 From $89 on View for Better 2024 EBITDA Margins, Keeps Sector Perform Rating	23-05-04	MT
RBC Lifts Price Target on Bio-Techne to $89 From $88, Maintains Sector Perform Rating	23-04-14	MT
RBC Lifts Price Target on Bio-Techne to $89 From $88, Maintains Sector Perform Rating	23-04-13	MT
RBC Trims Price Target on Bio-Techne to $88 From $89 After Fiscal Q2 Miss, Maintains Sector Perform Rating	23-02-06	MT
SVB Securities Lowers Price Target on Bio-Techne to $110 From $125, Maintains Outperform Rating	23-02-03	MT
Wells Fargo Upgrades Bio-Techne to Equalweight From Underweight, Price Target is $90	23-01-10	MT
Deutsche Bank Initiates Coverage on Bio-Techne With Buy Rating, $100 Price Target	22-12-14	MT
Citigroup Upgrades Bio-Techne to Buy From Neutral, Adjusts Price Target to $100 From $81.25	22-12-12	MT
RBC Initiates Bio-Techne at Sector Perform, Sets Price Target at $89, Says Revenue Targets Look 'Too High'	22-12-07	MT
Stephens Adjusts Bio-Techne's Price Target to $105 From $420 After Stock Split, Keeps Overweight Rating	22-12-05	MT
SVB Securities Adjusts Price Target on Bio-Techne to $500 From $550, Maintains Outperform Rating	22-11-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

64.06 USD

Average target price

80.43 USD

Spread / Average Target

+25.56%

High Price Target

95 USD

Spread / Highest target

+48.30%

Low Price Target

65 USD

Spread / Lowest Target

+1.47%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bio-Techne Corporation

Deutsche Bank Securities
RBC Capital Markets
Stephens Inc.
Stifel Nicolaus
UBS
KeyBanc Capital Markets
William Blair & Co.
Baird
SVB Securities LLC
Wells Fargo Securities
Citigroup
SVB Leerink
Argus

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar